cerrar
Tagged with P

The IFPMA’s New Code of Practice: PharmaBoardroom Readers…
Across the month of January, we at PharmaBoardroom surveyed our executive readership on attitudes towards the International Federation of…

NEW Special Pharma Report on Algeria
Click here to download the Healthcare & Life Sciences Review Algeria 2019 report. Algeria, Africa’s largest country by area, stands…

Turkish Pharma: Imports & Exports Snapshot
Imports and exports in Turkish pharma between 2010 and 2017. Pharmaceutical exports grew to a total of USD 898 million in 2017.…

The UK to Incentivise Big Pharma Firms to Develop New…
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were…

Hospital Investments in Turkey: Bucking the Trend
Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment.…

Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs: Ecuador
An intro to the legal situation for medical cannabis, cannabinoid drugs and opioids in Ecuador. Prepared in association with Corral Rosales, a leading…

India’s Drug Regulatory Reforms: Building Trust
Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country…

Top 20 Pharma Companies in France (2018)
The Top 20 pharma companies in France, ranked by total turnover at ex-manufacturer prices for 2018. Swiss giant Novartis is in first place with a EUR…

Mexico’s Healthcare System: Perspectives from the Pharma…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more…

Armağan Vurdu – General Secretary, IMMIB, Turkey
Armağan Vurdu, general secretary of the Istanbul Minerals and Metals Exporters Association (IMMIB) highlights the strategic importance of the…

4+7: China’s New Volume-Based Purchasing Policy
In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s…

Megatrends from the 2019 Deloitte Life Sciences Outlook
Deloitte's Global Life Sciences & Health Care industry leader, Greg Reh gives us an exclusive insight into their forecast for 2019's industry…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here